European journal of medicinal chemistry
Cure8 research brief
Why This Matters
The study identifies a new selective HDAC6 inhibitor with anti-inflammatory effects in cells and a mouse colitis model, which could inform early-stage drug discovery for IBD.
Who Should Pay Attention
Researchers and drug developers focused on IBD therapeutics, translational scientists studying HDAC biology, and clinicians interested in future IBD treatment mechanisms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers designed and synthesized a series of anthranilamide derivatives based on a marine natural product and tested them in laboratory assays. Compound 17 showed strong inhibition of IL-6 and IL-1β at 10 μM in cell-based assays and was identified as a selective HDAC6 inhibitor by biochemical testing and molecular docking.
In mice with DSS-induced colitis, compound 17 reportedly improved colonic pathology, indicating anti‑inflammatory activity in an animal IBD model. The work is preclinical and presents compound 17 as a lead candidate for further development rather than an approved treatment.
Keep In Mind
This is an abstract-level report of preclinical laboratory and animal work (structured content depth: abstract). Findings describe a lead compound and are not clinical evidence. Human relevance requires extensive follow-up.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of medicinal chemistry
AuthorsZhou Y, Ji G, Chen Y +10 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
From discovery to mechanism: novel anti-ulcerative colitis meroterpenoids act through the PI3K/IκB-α/MAPK pathway.
The study reports a newly discovered class of marine-derived meroterpenoids and identifies a lead compound that reduced inflammatory markers and improved colitis in mice, which could eventually inform new drug...
Design, synthesis, and evaluation of indole-pyridine chalcone derivatives as novel HK2 inhibitors to modulate macrophage glycolysis and inflammation for IBD treatment.
The study identifies HK2 inhibition as a potential mechanism to shift pro-inflammatory macrophages and reduce intestinal inflammation in preclinical models, which could guide future drug development for IBD.
Identification of CD40 as the target of artemisinin via targeted degradomics for ulcerative colitis.
This study suggests an existing antimalarial drug, artemisinin, may reduce inflammation and improve gut barrier function in a mouse model of ulcerative colitis by targeting CD40 — a pathway relevant to immune-driven gut...